{"id":847920,"date":"2025-05-07T07:05:13","date_gmt":"2025-05-07T11:05:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reports-first-quarter-2025-financial-results-and-raises-guidance\/"},"modified":"2025-05-07T07:05:13","modified_gmt":"2025-05-07T11:05:13","slug":"avadel-pharmaceuticals-reports-first-quarter-2025-financial-results-and-raises-guidance","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/avadel-pharmaceuticals-reports-first-quarter-2025-financial-results-and-raises-guidance\/","title":{"rendered":"Avadel Pharmaceuticals Reports First Quarter 2025 Financial Results and Raises Guidance"},"content":{"rendered":"
\n

\n — Generated $52.5 million in net revenue from sales of LUMRYZ\u2122, a 93% increase over the first quarter of 2024 —<\/em>\n <\/p>\n

\n — 2,800 patients on LUMRYZ as of March 31, 2025, a net increase of 300 patients since December 31, 2024 and a 100% year over year increase over the first quarter of 2024 —<\/em>\n <\/p>\n

\n — Raises 2025 guidance; expects to generate $255 – $265 million in net product revenue and cash flow of $30 – $40 million, driven by 3,400 – 3,600 patients on LUMRYZ by year end —<\/em>\n <\/p>\n

\n — Federal Circuit ruled in Avadel\u2019s favor in appeal of Delaware Court injunction, allowing Avadel to seek and be granted FDA approval for LUMRYZ in Idiopathic Hypersomnia (IH) —<\/em>\n <\/p>\n

\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0— On track to complete enrollment in pivotal Phase 3 REVITALYZ\u2122 study evaluating efficacy and safety of LUMRYZ in IH by the end of 2025 — <\/em><\/p>\n

\n — <\/em>
\n Avadel management to host a conference call today at 8:00 a.m. ET<\/em>
\n —<\/em>\n <\/p>\n

DUBLIN, May 07, 2025 (GLOBE NEWSWIRE) — Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced its financial results for the first quarter ended March 31, 2025, and increased its 2025 financial guidance.<\/p>\n

\u201cWe are pleased with the strong progress achieved in the first quarter of 2025, as we have seen improvements across all patient demand metrics for LUMRYZ, including patient starts, persistency rates, and net patients on therapy. As a result, we are raising our full year 2025 guidance and expect $255 – $265 million in net revenue and 3,400 – 3,600 patients on therapy by year end,\u201d said Greg Divis, Chief Executive Officer of Avadel Pharmaceuticals. \u201cThe improvements we are seeing are driven by the investments we made at the beginning of the year to expand our customer-facing teams, allowing us to deliver more personalized support and strengthen engagement with both patients and providers. We continue to build momentum and remain confident in our ability to deliver our growth plan and unlock the billion-dollar potential of LUMRYZ.\u201d<\/p>\n

\u201cIn addition, yesterday\u2019s favorable Federal Circuit decision allows Avadel to initiate new clinical trials, conduct open-label extension studies, and most importantly, pursue FDA approval for LUMRYZ\u2019s use in idiopathic hypersomnia (\u201cIH\u201d) and additional indications. With enrollment in our pivotal Phase 3 trial in IH on track to complete before year end, we believe LUMRYZ is well positioned to unlock this meaningful market opportunity where, if approved, LUMRYZ\u2019S extended-release, once-nightly dosing has the potential to offer even greater benefit than in narcolepsy, and we look forward to providing future updates.\u201d<\/p>\n

\n First Quarter Highlights and 2025 Guidance:<\/strong>\n <\/p>\n